Sustainability Report 2024
Ensuring ongoing access to sought-after medicinal products for patients is becoming increasingly important, but many regulatory, logistical, and financial hurdles must be overcome. There is also a growing need to provide access to unlicensed, pre-approved drugs.
In this whitepaper, we will explore how pharma and biotech companies can devise efficient medicines access strategies and, in doing so, maximise the potential of their products while not only enabling continued access for patients with an unmet medical need but also reaching new patients on a global level.
Managed Access Program: A practical guide
Managed Access Programs are a key pillar of the drug development lifecycle, yet they remain widely misunderstood – both by the people who need them most and those trying to implement them. Part of the reason for this is language. There are many overlapping and inconsistently used terms in this field, which can confuse both […]
Celebrating 15 Years of BAP Pharma
This year marks an important milestone for BAP Pharma as we celebrate 15 years since the company was founded in 2011 by Dr. Bashir Parkar. Over that time, the company has grown from a specialist provider into a trusted global partner supporting clinical trials and medicines access programmes around the world. While the business has […]
In search of certainty: How we help Biotechs save lives sooner
How we help Biotechs save lives sooner Patients with rare diseases face all kinds of challenges in their lives, including accessing the most up to date treatments. A serious health condition is hard enough, without compounding it with uncertainty around medication. Biotech innovation is constantly exploring new solutions, but connecting them – all of them […]
BAP Pharma Reinforces Its Commitment to the Local Community in Höchstädt, Germany.
Since establishing its operations in Höchstädt in 2020, BAP Pharma GmbH has placed strong emphasis on being an active and responsible member of the local community. Beyond its role as a global provider of pharmaceutical services, the company is committed to making a positive social impact in the regions where it operates. This commitment was […]
Partnering to Empower Patients: A Collaboration with Rare Beacon on Early Access Programs
How It Started One of our key focuses at BAP Pharma is to actively engage with patient advocacy groups (PAGs), particularly in the rare disease space. As part of our mission to support access to unlicensed medicines, we believe it’s essential to raise awareness about early access, compassionate use, and post-trial access programs – and […]
Agile Approach to Comparator Sourcing
The Sponsor was initially unsure of their enrolment and subsequently experienced rapid patient enrolment, which led to the need for increased quantities of materials and an unexpected change in their packaging schedule. Their on-going forecast identified a risk in both the timely fulfilment and expedited delivery to meet their revised patient recruitment timelines.
The Power of Collaboration: Why the Success of an Early Access Program Depends on Stakeholder Engagement
Early Access Programs (EAPs) offer a critical pathway for patients with serious or life-threatening conditions to access potentially life-saving treatments before they become commercially available. While these programs hold enormous promise, their success is never the result of one single effort. They depend on the collaboration of a wide range of stakeholders – from regulatory […]
Revolutionizing Clinical Trial Supply: How BAP Pharma’s Agile Approach Redefines Comparator Sourcing
Clinical trials are the backbone of medical innovation, but they require precision, efficiency, and adaptability to succeed. Traditional comparator sourcing and clinical labelling strategies often come with rigid timelines, financial strain, and inefficiencies that can hinder progress. At BAP Pharma, we offer a smarter approach—one that enhances agility, minimizes risk, and optimizes costs. The Challenge: […]